Supramolecular Nanoparticles of Insulin and Pentapeptide for Inhibition of Fibrillation and Controlled Release.
Despite their obvious advantages of making insulin injections less frequent and reducing discomfort for diabetic patients, various controlled release formulations of insulin still have some problems caused by the fibrillation of protein. Here, we demonstrate that pentapeptide FVPRK inspired from the C-terminal of the insulin receptor α-CT can form supramolecularassembled nanoparticles with insulin, showing a controlled release of insulin and an inhibition effect of insulin fibrillation. These nanoparticles were proved non-toxic through cytotoxicity study and the assembling mechanisms was explored by computer simulations, indicating that the strong π-π interaction between C-terminus of insulin B-chain and Phe of the pentapeptide may provide the corresponding driving force. These results suggest that supramolecular nanoparticles composed of insulin and pentapeptide have the potential to improve insulin therapy.